Respira Therapeutics, Inc.
Major Drugs - Palo Alto, California, US
Respira Therapeutics, Inc. Employees
Respira Therapeutics, Inc. Senior Management
Respira Therapeutics, Inc. Details
Respira Therapeutics is developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of the lung. Respira combines proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches to develop novel therapeutics that deliver the drug where it needs to be —in the lung and lung periphery, instead of in the oropharyngeal cavity. Respira’s lead product candidate, RT234-PAH, has received FDA Orphan Drug Designation for Pulmonary Arterial Hypertension and is in Phase 2 clinical trials as a first-in-class inhaled therapeutic for as-needed use to provide acute relief for the most commonly reported symptoms in PAH patients.
Respira Therapeutics, Inc. Technologies
Email Providers
Outlook
Load Balancers
Apache
Fonts
Google Font API
CSS and JavaScript Libraries
Bootstrap Framework
Other
Mobile Friendly
Analytics and Tracking
Google Analytics